Alkermes competitors

John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.

Mr. Loewald joined Cambrex in September 2020 and currently serves as Chief Executive Officer. Mr. Loewald is a 15-year veteran of Thermo Fisher Scientific, where he served in several senior executive roles during his tenure, including Chief Commercial Officer, President of the Analytical Instruments Group, President of the Laboratory Products Group, and President of the Laboratory Equipment and Environmental Instrument Divisions. Earlier in his career he held leadership positions at Tyco International and General Electric. Mr. Loewald currently serves on the Board of Directors of Harvard BioScience, a global developer, manufacturer and marketer of a broad range of solutions to advance life science.

Robert Kramer is a President & Chief Executive Officer at EMERGENT BIOSOLUTIONS INC., Board Member at EMERGENT BIOSOLUTIONS INC., and Interim Exec VP:Services at EMERGENT BIOSOLUTIONS INC. and is based in Lansing, Michigan. He has experience at PHARMACIA CORP and has worked as Pres:Biosciences Div at EMERGENT BIOSOLUTIONS INC., Consultant at EMERGENT BIOSOLUTIONS INC., and President at Emergent Biodefense Ops Lansg. Robert works or has worked as Chief Executive Officer at Emergent Biodefense Operations. He studied at WESTERN KENTUCKY UNIVERSITY between 1980 and 1983 and Clemson University between 1975 and 1979.

Executive Officer with over 20 years of transactional and operational experience in venture capital backed startups to mature fully integrated organizations in the biotechnology, medical device, and pharmaceutical industries. Completed strategic transactions & shareholder exits totaling |$530M, venture capital/royalty fundraising totaling |$70M, and public offerings (IPO and secondary) totaling |$200M. Established strategy as part of executive management teams, growing revenues to |$300M, hired and led senior (C-Level to VP level) leadership teams, and secured multiple FDA PMA, NDA, and 510(k) approvals. Functional leadership in and P&L responsibility for market development, international sales distribution, M&A/business development, R&D, regulatory & clinical affairs, manufacturing & logistics, patent & legal affairs, quality operations, facilities, finance, and information technology.Areas of expertise include: Organization Transformation, R&D, Strategic Planning, Integrating Acquisitions and Products, Business Development, Investor & Shareholder Relations, Board of Directors and KOL Engagement, Crisis Management & Restructuring, Product Development, FDA & Global Regulatory Approvals, Lean & Continuous Improvement, Financial Analysis, and P&L/Cost Management.

Matthew E. Monaghan is an independent director who joined the Board in October 2016, and is a member of the Audit Committee and Nominating and Corporate Governance Committee. Mr. Monaghan currently serves as President and Chief Executive Officer at Invacare Corporation (NYSE:IVC) (“Invacare”), a medical device manufacturer for the home and long-term healthcare markets, a position he has held since April 2015. Mr. Monaghan was named Chairman of the Invacare Board in May 2015. He previously served as Senior Vice President, Global Hips and Reconstructive Research for Zimmer Biomet Holdings, Inc. (formerly known as Zimmer Holdings, Inc.) (“Zimmer”), a global company that designs, develops, manufactures and markets orthopedic reconstructive, spinal and trauma devices, dental implants, and related surgical products from 2014 to 2015. Mr. Monaghan also has served as Operating Executive for Texas Pacific Group from 2006 to 2009 and at Cerberus Capital Management from 2003 to 2005. He started his career with 13 years in the aerospace, medical and other industrial businesses of General Electric. Mr. Monaghan is a trustee of Cleveland Clinic Avon Lake Hospital. Mr. Monaghan was a member of the board of directors of CD Diagnostics, Inc. from 2012 to 2016 and served as the chairman of the Audit Committee from 2012 to 2015 and as chairman of the board from 2015 to 2016. He holds a Bachelor’s degree in Mechanical Engineering from Cornell University, a Master’s degree in Mechanical Engineering from MIT and an MBA from INSEAD Business School in France.

Michael Castagna is a Board Member at MANNKIND CORP and Chief Executive Officer at MANNKIND CORP and is based in Westlake Village, California. He has worked as Vice President & Head, Biopharmaceuticals North America at Sandoz; Director, Endocrinology Marketing at Healthcare Business of Merck; and VP/Global Head:Commercial at Amgen. Michael attended Massachusetts College of Pharmacy and Health Sciences between 2012 and 2014, The Wharton School between 2003 and 2005, and Philadelphia College of Pharmacy & Science.

Richard Maradie is a Chief Executive Officer at NOVAVAX INC and is based in Rockville, Maryland.

CEO at T2 Biosystems | Board Member | Heart Transplant Recipient | Sepsis Survivor | Best Selling Author | Inspirational Speaker

Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA). Joined XOMA in 2009 and was appointed to the CEO role in late 2016. In early 2017, Mr. Neal led XOMA through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company and transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and knowhow. In addition to his role at XOMA, Mr. Neal currently serves as a Director at Leading Biosciences, a clinical stage biotech company based in Carlsbad, CA. Mr. Neal has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Prior to XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos Inc., a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Mr. Neal was Chief Executive Officer. At Iconix, Mr. Neal established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, MO.